The latest IMS Institute for Healthcare Informatics assessment of 2013's prescription drug use shows that 2.3% of prescriptions account for 30% of a patient's out-of-pocket prescription costs.
Express Scripts said treatments for diabetes are the most expensive of the traditional medications, while specialty drugs are eating up a significant portion of total drug spend.
A report indicates that Sovaldi's high price may hurt health-insurance investors.
The professional association says it's necessary, because high prices do not indicate impact.
The UK's National Institute for Health and Care Excellence says it bounced Bayer's drug for failing to compare itself to current treatments, and Sanofi's over cost.
Insurers and state agencies are wondering if and how they can cover the $84,000 hep. C drug.
The UK watchdog wants to know what's behind the rare-disease drug's high price.
Germany's price transparency requirement has the industry worried other markets will demand lower prices.
The fast-tracked drug netted another indication today, this one for a form of leukemia. Lower dosage of the drug for that indication shrinks the price compared to lymphoma.
The third Pharmacy Benefit Management Institute specialty medication survey expects specialty medications, which average around $3,000 per month per patient, will account for 50% of the drug spend within four or five years.
The drug maker is reportedly talking low rates for India's market.
If the HCV drug's trajectory continues, it could exceed Q1 and 2014 sales forecasts, despite payers' reported unease over price.
The price watchdog said Sanofi's oral MS drug Aubagio is a go. The decision follows a September directive to prove the drug's cost-effectiveness.
Generics accounted for almost 75% of dispensed drugs in 2012, according to CMS researchers.
CMS is proposing a rule that could change how antidepressants get on Medicare Part D formularies.
Our year-end list captures the 10 that sparked heaviest interest.
The drugmaker and partner AstraZeneca say they can't find a comfortable pricing arrangement with German insurers.
The National Health Service is expected to have a $49-billion deficit by 2020.
The PBM encourages step-therapy to control costs.
The catch is the difference between sales and revenues. Generics will continue to be a force, and small-audience drugs will become increasingly important.
Domestic manufacturers are being pressured to offer domestic discounts to international clients.
The drugmaker blasted the price-control agency for being shortsighted and underestimating the industry's role in health and savings.
Subscribers will be able to use co-pay cards on Obamacare exchanges.
A wide-ranging piece recounts the pushback from oncologists that led to a decrease in the price of Zaltrap.
The short answer: we're not financially prepared for a slowly aging, healthy population, according to a recently published analysis.
AbbVie and Galapagos go after cystic fibrosis; FDA's NME approval pace slows; government shutdown could slow ad-com votes; and a report shows privately insured patients had emptier pockets in 2012 than 2011
Researchers says growth will average 5.8% a year between 2012 and 2022. They also anticipate generics will hit a leveling-off point that will drive average Rx prices upwards
CDC finds that non-Medicare adults make up the majority of preventable heart attack and stroke cases; a Facebook study shows groups can influence HIV screening; and a Shire ADHD drug gets a "no" from Germany
Australia's price watchdogs are assessing the value of BMS cancer drug Yervoy; why a Phase II weight drug from Zafgen could open up the category; GSK halts a Crohn's trial; and Shire extends Santaris rare-disease collaboration
GSK seeks a new ovarian cancer indication for Votrient; a bill that would extend exclusivity for some combination drugs is introduced in Congress; Otsuka's tolvaptan gets a thumbs-down from an FDA advisory committee; NICE rejects Roche's Perjeta; India tosses Herceptin patents; and China revokes Gilead's patent on Viread